Table of Content

1. Table of Contents
1.1 List of Tables
1.2 List of Figures


2. Executive Summary
2.1 Report Guide
2.2 Methodology
2.3 Market Segmentation
2.4 NASH Biomarkers (Non alcoholic Steatohepatitis) Market- Key Findings, 2020


3. Strategic Imperatives on Global NASH Biomarkers (Non alcoholic Steatohepatitis) Market
3.1 COVID-19 Impact Analysis
3.2 Market Trends- Across Types, Applications, End User Types, Countries
3.3 Insights into Main Market Categories
3.4 Market Drivers and Restraints
3.5 Growth Opportunities Critical for Future Success
3.6 Key NASH Biomarkers (Non alcoholic Steatohepatitis) Companies


4. NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026 Outlook By Type
4.1 Hepatic fibrosis biomarkers
4.2 Apoptosis biomarkers
4.3 Oxidative stress biomarkers
4.4 Serum biomarkers
4.5 Other biomarkers


5. NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026 Outlook By End User
5.1 Hospitals
5.2 Diagnostic labs
5.3 Pharma & CRO industry
5.4 Inhaler technology


6 Asia Pacific NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026
6.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to Asia Pacific market
6.2 Top Applications contributing to Asia Pacific NASH Biomarkers (Non alcoholic Steatohepatitis)
6.3 Top countries contributing to Asia Pacific NASH Biomarkers (Non alcoholic Steatohepatitis)


7 Europe NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026
7.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to Europe market
7.2 Top Applications contributing to Europe NASH Biomarkers (Non alcoholic Steatohepatitis)
7.3 Top countries contributing to Europe NASH Biomarkers (Non alcoholic Steatohepatitis)


8 North America NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026
8.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to North America market
8.2 Top Applications contributing to North America NASH Biomarkers (Non alcoholic Steatohepatitis)
8.3 Top countries contributing to North America NASH Biomarkers (Non alcoholic Steatohepatitis)


9 South and Central America NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026
9.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to South and Central America market
9.2 Top Applications contributing to South and Central America NASH Biomarkers (Non alcoholic Steatohepatitis)
9.3 Top countries contributing to South and Central America NASH Biomarkers (Non alcoholic Steatohepatitis)


10 Middle East Africa NASH Biomarkers (Non alcoholic Steatohepatitis) Market Value Outlook to 2026
10.1 Leading NASH Biomarkers (Non alcoholic Steatohepatitis) Types contributing to Middle East Africa market
10.2 Top Applications contributing to Middle East Africa NASH Biomarkers (Non alcoholic Steatohepatitis)
10.3 Top countries contributing to Middle East Africa NASH Biomarkers (Non alcoholic Steatohepatitis)


11 Business Profiles of Leading Companies
11.1 Business Description, SWOT and Financial Analysis of Companies in NASH Biomarkers (Non alcoholic Steatohepatitis) market
11.2 Allergan Plc
11.3 AstraZeneca
11.4 Boehringer Ingelheim
11.5 Bristol-Myers Squibb Company
11.6 GENFIT SA
11.7 Gilead Sciences
11.8 Novartis AG
11.9 Novo Nordisk A/S
11.10 Prometheus Laboratories Corp.
11.11 Pfizer Inc.?


12 Recent Industry Developments


13 Appendix
13.1 OGAnalysis Expertise
13.2 Sources and Methodology
13.3 Contacts